Company

The diabetes battle: Will Novo’s oral GLP-1 knock Trulicity off its perch?

  • December, 11 2018
  • 514

Timing is of the essence for Novo Nordisk. The Danish company may use its priority review voucher to accelerate oral GLP-1 agonist candidate, semaglutide, past the regulators – though a decision is not confirmed. Buying a few more weeks – or months – to e

Company

Bayer Cuts Internal R&D, Looking Outside

  • December, 11 2018
  • 358

Bayer’s late November announcement of 12,000 job cuts and a focus on ‘collaborative research models’ and ‘external innovations’ to fuel pharma R&D is not a surprise. Rumors had been swirling for months in the German press. Bayer board member and innov

Related Videos
Oliver Spray Analyst
Oliver Spray Analyst

M&A Outlook for 2018

Amanda Mucklus Analyst
Amanda Mucklus Analyst

Diversification Strategy

Pharma Intelligence
Pharma Intelligence

Biosimilars Battlegrounds

Pharma Intelligence
Pharma Intelligence

Q4 2018 Outlook Webinar